Drug Shortage Report for RIVASTIGMINE
Report ID | 236658 |
Drug Identification Number | 02417014 |
Brand name | RIVASTIGMINE |
Common or Proper name | RIVASTIGMINE |
Company Name | PRO DOC LIMITEE |
Market Status | MARKETED |
Active Ingredient(s) | RIVASTIGMINE |
Strength(s) | 4.5MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL ORAL |
Packaging size | 100 |
ATC code | N06DA |
ATC description | ANTI-DEMENTIA DRUGS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2024-10-07 |
Actual start date | 2024-10-09 |
Estimated end date | Unknown |
Actual end date | |
Shortage status | Actual shortage |
Updated date | 2024-11-29 |
Company comments | Looking to transfert to another supplier |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 2925 BOULEVARD INDUSTRIEL LAVAL, QUEBEC CANADA H7L 3W9 |
Company contact information | 2925 BOULEVARD INDUSTRIEL, LAVAL QC, H7L 3W9 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v7 | 2024-11-29 | French | Compare |
v6 | 2024-11-29 | English | Compare |
v5 | 2024-10-10 | French | Compare |
v4 | 2024-10-10 | English | Compare |
v3 | 2024-10-08 | English | Compare |
v2 | 2024-09-04 | French | Compare |
v1 | 2024-09-04 | English | Compare |
Showing 1 to 7 of 7